mrd-guided surveillance in locally advanced mid-low rectal cancer (surveillance-iii)

Conditions: Colorectal Cancer (CRC)

Summary: this study aims to explore the relationship between minimal residual disease (mrd) status and disease recurrence in patients with locally advanced mid-low rectal cancer. mrd refers to the presence of cancer cells that remain in the body after treatment but are undetectable by traditional imaging methods. the study will use a blood-based circulating tumor dna (ctdna) methylation test to assess its ability to predict cancer recurrence and survival outcomes. patients who are newly diagnosed with ct3/n+, m0 mid-low rectal cancer (tumor ≤10 cm from the anal verge) and are eligible for curative-intent treatment will be enrolled. blood samples will be collected at multiple time points, including before neoadjuvant therapy, before surgery, after surgery, and during follow-up visits over three years. the study will compare mrd status with disease-free survival (dfs), recurrence-free survival (rfs), overall survival (os), and the time it takes for mrd to detect recurrence compared to standard imaging methods. the goal is to determine whether mrd monitoring can provide an early warning of cancer recurrence and help guide treatment decisions. this study may offer valuable insights into improving postoperative surveillance and personalized treatment strategies for rectal cancer patients.

this is a multicenter, prospective, observational study designed to evaluate the effectiveness of ctdna-based mrd monitoring in predicting disease recurrence and survival outcomes in patients with locally advanced mid-low rectal cancer. the study will enroll 139 patients who have not previously received chemotherapy, radiotherapy, or targeted therapy. key objectives primary objective: to explore the correlation between mrd status and disease-free survival (dfs) in locally advanced mid-low rectal cancer patients. secondary objectives: to assess the relationship between mrd status and 1-year/2-year recurrence-free survival (1yrfs, 2yrfs). to evaluate the association between mrd status and overall survival (os). exploratory objectives: to determine the average time by which mrd detection precedes imaging-based detection of disease recurrence. to assess the correlation between post-neoadjuvant therapy mrd status and pathological complete response (pcr). study design patients will undergo blood sampling at key time points: baseline (pre-neoadjuvant therapy) pre-surgery (0-7 days before surgery) post-surgery (7±2 days after surgery) follow-up visits at 1, 3, 6, 9, 12, 18, 24, and 36 months post-surgery mrd status will be assessed using a ctdna methylation-based pcr test, which provides a rapid, cost-effective alternative to traditional ngs-based methods. statistical analysis kaplan-meier survival analysis will be used to estimate dfs, rfs, and os. cox proportional hazards models will assess whether mrd status serves as an independent prognostic factor for recurrence. multivariate analysis will adjust for clinical variables, including tumor burden and treatment history. ethical considerations the study adheres to the principles of the declaration of helsinki and chinese good clinical practice (gcp) guidelines. informed consent will be obtained from all participants, and privacy and confidentiality will be strictly maintained. expected outcomes this study aims to validate the clinical utility of ctdna-based mrd monitoring in predicting recurrence and survival outcomes for locally advanced mid-low rectal cancer patients. if successful, mrd testing may offer a more effective tool for postoperative surveillance and treatment planning, allowing for earlier interventions and improved long-term outcomes.

Eligibility criteria:
inclusion criteria: 1） age 18-80 years old, male or female; 2) histologically confirmed diagnosis of rectal adenocarcinoma (i.e., adenoepithelial carcinoma, including adenocarcinoma, mucinous carcinoma, imprinted cell carcinoma, and undifferentiated carcinoma; excluding adenosquamous carcinoma); 3) preoperative clinical stage ct3 /n+, m0, the lower edge of the tumor is ≤10cm from the anal verge, and no surgical resection is performed; (4) not receiving chemotherapy, radiotherapy, targeted therapy or other anti-tumor therapy; 5) radical surgery is available; 6) ecog score 0-1; 7) subjects voluntarily enrolled in this study and signed the informed consent, good compliance, follow the planned schedule and actively cooperate with the return to the hospital for regular clinical follow-up and necessary treatment. exclusion criteria: 1. previous other malignant tumors (including non-adenocarcinoma colorectal cancer); 2. previously received other anti-tumor therapy; 3. pregnant and lactating women; (4) patients with other medical conditions that, in the judgment of the investigator, may interfere with follow-up and short-term survival; 5) subjects have other factors that may lead to forced termination of this study, such as other serious illnesses (including mental illness, infectious diseases, fever ≥38℃, etc.) that require combined treatment, serious laboratory test abnormalities, accompanied by family or social factors that will affect the safety of the subjects, or the collection of data and samples.